[go: up one dir, main page]

DE69633919D1 - Mehrzweckvakzine gegen umhüllte viren - Google Patents

Mehrzweckvakzine gegen umhüllte viren

Info

Publication number
DE69633919D1
DE69633919D1 DE69633919T DE69633919T DE69633919D1 DE 69633919 D1 DE69633919 D1 DE 69633919D1 DE 69633919 T DE69633919 T DE 69633919T DE 69633919 T DE69633919 T DE 69633919T DE 69633919 D1 DE69633919 D1 DE 69633919D1
Authority
DE
Germany
Prior art keywords
mhc molecules
vaccine compositions
viruses
virus
environed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69633919T
Other languages
English (en)
Other versions
DE69633919T2 (de
Inventor
Donald L Morton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
John Wayne Cancer Institute
Original Assignee
John Wayne Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Wayne Cancer Institute filed Critical John Wayne Cancer Institute
Publication of DE69633919D1 publication Critical patent/DE69633919D1/de
Application granted granted Critical
Publication of DE69633919T2 publication Critical patent/DE69633919T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69633919T 1995-04-24 1996-04-24 Mehrzweckvakzine gegen umhüllte viren Expired - Fee Related DE69633919T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/427,034 US6168787B1 (en) 1995-04-24 1995-04-24 Pluripotent vaccine against enveloped viruses
US427034 1995-04-24
PCT/US1996/005731 WO1996033734A1 (en) 1995-04-24 1996-04-24 A pluripotent vaccine against enveloped viruses

Publications (2)

Publication Number Publication Date
DE69633919D1 true DE69633919D1 (de) 2004-12-30
DE69633919T2 DE69633919T2 (de) 2005-12-01

Family

ID=23693219

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633919T Expired - Fee Related DE69633919T2 (de) 1995-04-24 1996-04-24 Mehrzweckvakzine gegen umhüllte viren

Country Status (8)

Country Link
US (2) US6168787B1 (de)
EP (1) EP0830140B1 (de)
JP (1) JPH11509521A (de)
AT (1) ATE283065T1 (de)
AU (1) AU708327B2 (de)
CA (1) CA2219339A1 (de)
DE (1) DE69633919T2 (de)
WO (1) WO1996033734A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19626614A1 (de) * 1996-07-02 1998-01-08 Immuno Ag Komplex aus Antigen und Zellbestandteil, Impfstoffzusammensetzung, welche den Komplex enthält, pharmazeutische Präparation sowie Verfahren zur Herstellung des Komplexes
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1131633A2 (de) * 1998-11-16 2001-09-12 Board of Regents, The University of Texas System Hiv spezifische zelleninduktion
US20060211012A1 (en) * 2005-03-21 2006-09-21 Network Immunology Inc. Mhc class ii as a preventive vaccine against hiv infection
US20070128209A1 (en) * 2005-03-21 2007-06-07 Network Immunology Inc. Vaccine based method for protection against hiv infection
US8557257B2 (en) * 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
CA2663034C (en) 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
CA2674244A1 (en) * 2006-12-28 2008-07-10 Saint Louis University Identification of multivalent viral envelope protein epitopes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5882654A (en) * 1989-11-03 1999-03-16 Morton; Donald L. Polyvalent melanoma vaccine
US5840317A (en) * 1989-11-03 1998-11-24 Morton; Donald L. Composition comprising tumor cell lines containing GD2 ganglioside GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen
GB9201023D0 (en) 1992-01-17 1992-03-11 Medical Res Council Vaccines
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods

Also Published As

Publication number Publication date
EP0830140B1 (de) 2004-11-24
EP0830140A1 (de) 1998-03-25
US6168787B1 (en) 2001-01-02
ATE283065T1 (de) 2004-12-15
JPH11509521A (ja) 1999-08-24
AU708327B2 (en) 1999-08-05
WO1996033734A1 (en) 1996-10-31
CA2219339A1 (en) 1996-10-31
US20030185806A1 (en) 2003-10-02
AU5573196A (en) 1996-11-18
DE69633919T2 (de) 2005-12-01

Similar Documents

Publication Publication Date Title
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
ES2129386T3 (es) Vacuna contra la gripe.
BR0107857A (pt) Proteìnas compreendendo regiões conservadas de antìgeno nhha de superfìcie de neisseria meningitidis
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
EE200200507A (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
RU95105518A (ru) Применение мутантов вируса герпеса, вакцина
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
HUP0500722A2 (hu) Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
Karpenko et al. Results of phase I clinical trials of a combined vaccine against HIV-1 based on synthetic polyepitope immunogens
EP0868522A4 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, zusammensetzungen dessen und methoden zur herstellung und verwendung
Delman et al. Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer
Naveed et al. Immune modulatory potential of anti-idiotype antibodies as a surrogate of foot-and-mouth disease virus antigen
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
WO2024031045A3 (en) Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee